Fig. 6 Innate and adaptive immunity, but not ADCC, contributes to M7824 antitumor activity. Innate and adaptive immunity, but not ADCC, contributes to.

Slides:

Advertisements

Similar presentations

Synergistic antitumor effect of anti-CD40/CpG and 14

Advertisements

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

An anti-CD20–IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma by Stephen D. Gillies, Yan Lan, Steven Williams,

Fig. 4. PVSRIPO infection of DCs is sublethal, is marginally productive, and induces sustained proinflammatory cytokine production. PVSRIPO infection of.

Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.

Volume 15, Issue 2, Pages (February 2007)

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Triggering PD-1 in B cells suppresses tumor-specific immunity and promotes disease progression. Triggering PD-1 in B cells suppresses tumor-specific immunity.

Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.

Fig. 8. In vivo suppression of MM by CMLD

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

PVSRIPO-mediated APC activation occurs in immunosuppressive conditions

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 3. Fc fusion GDF15 molecules improve metabolic parameters in obese mice and obese cynomolgus monkeys. Fc fusion GDF15 molecules improve metabolic.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

PD-1 blockade enhances elotuzumab efficacy in mouse tumor models

Fig. 1. Serum HBsAg, HBcrAg, and HBeAg reduction in human patients treated with a single dose of ARC-520. Serum HBsAg, HBcrAg, and HBeAg reduction in human.

Volume 13, Issue 1, Pages (January 2006)

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

The absence of ADCC by nivolumab in vitro.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Fig. 2. Circulating VEGF in GCA patients up-regulates microvascular endothelial Jagged1. Circulating VEGF in GCA patients up-regulates microvascular endothelial.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor

Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein by Rupali Das, Peng Guan, Susan J. Wiener,

Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.

Fig. 3. TKI sensitivity assessed by the MANO method.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 6 Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing mice. Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing.

CD facilitates RCT in vivo and promotes urinary cholesterol excretion

Fig. 3 Agonists of innate immunity are effective only when released locally from the hydrogel. Agonists of innate immunity are effective only when released.

Fig. 4 Surgery initiates a systemic inflammatory response that triggers the outgrowth of distant immunogenic tumors and can be inhibited by perioperative.

Selection of a 4-1BB-endodomain–based anti-EGFRvIII CAR construct

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 7 Vaccine-induced influenza-specific B cells are not maintained in peripheral blood. Vaccine-induced influenza-specific B cells are not maintained.

Fig. 4. Local application of FR provides prolonged protection against Gq-dependent airway constriction in normal and OVA-sensitized mice in vivo. Local.

Fig. 5 Extended local release of R848 increases the number of innate and adaptive antitumor immune cells and cytokines. Extended local release of R848.

Fig. 5 Treatment with an OX40 agonist antibody of 3-week-old HBVtgRag−/− mice or mice with chronic HBV disease results in an altered immune response to.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.

Fig. 2. CD treatment facilitates regression of murine atherosclerosis.

Immune-mediated tumor control by necroptotic cells requires NF-κB activation within dying cells but not MLKL-mediated cell lysis and DAMP release. Immune-mediated.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Fig. 2 In situ vaccination of CpG in combination with anti-OX40 antibody cures established local and distant tumors. In situ vaccination of CpG in combination.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 2 Extended local release of agonists of innate immunity prevents tumor recurrence and eliminates distal metastases. Extended local release of agonists.

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

Comparative effect of anti-TIM3 against experimental tumors.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

In vivo tumor targeting and biodistribution of radiolabeled anti-CEA Fab-H-2Kb/ova conjugates. In vivo tumor targeting and biodistribution of radiolabeled.

Fig. 3 Superiority of BAFF-R versus CD19-CAR T cells in a Burkitt lymphoma model is not due to greater tumor antigen density. Superiority of BAFF-R versus.

Ex vivo profiling of PD-1 blockade using MDOTS

Fig. 5 Effector function of MIH5 isotype variants.

CD38 regulates tumor growth and metastasis by adenosine-mediated CD8+ T-cell suppression. CD38 regulates tumor growth and metastasis by adenosine-mediated.

Presentation transcript:

Fig. 6 Innate and adaptive immunity, but not ADCC, contributes to M7824 antitumor activity. Innate and adaptive immunity, but not ADCC, contributes to M7824 antitumor activity. (A) μMt− mice were injected intramuscularly with 0.5 × 106 MC38 cells on day −7 and treated (n = 10 mice per group) on day 0 with isotype control (400 μg), M7824 (492 μg), or M7824 (492 μg) dosed with anti-murine CD4 (GK1.5; 100 μg), anti-murine CD8 (2.43; 100 μg), anti-murine CD4 + anti-murine CD8 (100 μg each), or anti-murine asialo GM1 (ASGM1; 50 μl). All injections were intravenous, except for ASGM1, which was intraperitoneal. Anti-murine antibodies were injected on day 0, and M7824 and isotype control were injected on days 1, 3, and 5. Tumor volumes (in cubic millimeters) were measured twice weekly and are presented as mean ± SEM. (B) Effect of M7824 on PBMC-mediated antibody-dependent cellular cytotoxicity (ADCC) against tumor cells. PBMCs from a human donor were cultured with 51Cr-labeled A431 human epidermoid carcinoma cells for 4 hours in the presence of different concentrations of M7824, anti–PD-L1, aglycosylated M7824, or isotype control. 51Cr release from labeled target cells was measured with a Wallac MicroBeta Trilux Liquid Scintillation Counter, and the percent lysis was determined. Data were fit to a four-parameter dose-response curve. The data shown are representative of five different human donors. (C) μMt− mice were injected intramuscularly with 0.5 × 106 MC38 cells on day −7 and treated (n = 15 mice per group) on day 0 with isotype control (133 μg), M7824 (55 or 164 μg), or aglycosylated M7824 (55 or 164 μg) on days 0, 2, and 4. Tumor volumes (in cubic millimeters) were measured twice weekly and are presented as mean ± SEM. ****P ≤ 0.0001 denotes a significant difference relative to M7824 treatment. Yan Lan et al., Sci Transl Med 2018;10:eaan5488 Published by AAAS